Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
US11633430B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 23, 2022 |
| Grant date | Apr 25, 2023 |
| Priority date | — |
| Expiry date | May 23, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/29
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.